Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INTROPIN vs ZOLPIMIST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dopamine is a direct agonist at dopamine (D1 and D2) and beta-1 adrenergic receptors, and at higher doses, alpha-1 adrenergic receptors. It also causes release of norepinephrine from sympathetic nerve terminals.
Zolpidem is a nonbenzodiazepine hypnotic that binds selectively to the benzodiazepine type 1 (BZ1) receptor on the alpha1 subunit of the GABA-A chloride ion channel complex, potentiating the inhibitory effects of GABA.
Hemodynamic support in cardiogenic shock,Hypotension not due to hypovolemia,Adjunct in cardiopulmonary resuscitation,Off-label: Bradycardia unresponsive to atropine
Insomnia (short-term treatment of insomnia characterized by difficulties with sleep initiation)
2-20 mcg/kg/min continuous IV infusion, titrated to achieve desired hemodynamic response. Typical initial dose: 5 mcg/kg/min.
5 mg orally once daily at bedtime, maximum 10 mg/day.
Approximately 2 minutes. Short half-life allows rapid titration by intravenous infusion; effects cease within 5-10 minutes of discontinuation.
Terminal elimination half-life is 2.8-3.2 hours in healthy adults. In elderly patients or those with hepatic impairment, half-life may be prolonged to 4-6 hours.
Metabolized in the liver, kidney, and plasma by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) to inactive metabolites.
Primarily metabolized by CYP3A4 and CYP1A2 (minor), with contributions from CYP2C9 and CYP2D6.
Primarily renal: 80% as unchanged drug and 20% as inactive metabolites (normetanephrine, homovanillic acid). Biliary/fecal excretion is negligible (<2%).
Renal (primarily as conjugated metabolites, approximately 80-85% of total clearance), fecal (approximately 10-15%), biliary (minor, <5%).
25%, primarily to albumin.
Approximately 92-95%, primarily to albumin.
0.2 L/kg (0.16-0.24 L/kg). Small Vd indicates limited extravascular distribution; compatible with rapid onset and offset.
0.8-1.3 L/kg, indicating extensive tissue distribution and penetration into the central nervous system.
Oral: less than 5% due to extensive first-pass metabolism (MAO and COMT). Intramuscular: variable but limited due to peripheral vasoconstriction; not recommended.
Oral: 30-40% (due to first-pass metabolism). Sublingual: 60-75%. Intranasal: 70-85%.
No specific GFR-based dose adjustment required; monitor for renal perfusion adequacy and adjust based on clinical response.
No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (GFR <30 m L/min) due to lack of data.
No specific Child-Pugh-based adjustment; use with caution in severe hepatic impairment due to altered metabolism.
Child-Pugh A: 5 mg once daily. Child-Pugh B: 2.5 mg once daily. Child-Pugh C: not recommended.
0.5-20 mcg/kg/min continuous IV infusion; typical initial dose 2-5 mcg/kg/min, titrated to effect.
Not approved for use in pediatric patients; safety and efficacy not established.
Start at lower end of dosing range (2-5 mcg/kg/min) due to increased sensitivity and comorbid conditions; titrate cautiously.
Initiate at 2.5 mg once daily at bedtime, maximum 5 mg/day due to increased sensitivity and risk of falls.
None
BOXED WARNING: Complex sleep behaviors including sleep-driving, sleepwalking, and other activities while not fully awake have been reported. Discontinue immediately if such behaviors occur.
Can cause ectopic heartbeats, tachycardia, angina, palpitations, vasoconstriction, and hypertension,May increase myocardial oxygen demand,Risk of tissue necrosis with extravasation,Use with caution in patients with occlusive vascular disease,Hypovolemia should be corrected before administration
Complex sleep behaviors (e.g., sleep-driving, sleepwalking) – discontinue immediately if occur,CNS depressant effects – impaired alertness and motor coordination; risk of next-day impairment,Worsening of depression or suicidal ideation,Abuse and dependence potential – use with caution in patients with history of substance abuse,Respiratory depression - use with caution in patients with compromised respiratory function
Pheochromocytoma,Uncorrected tachyarrhythmias,Hypersensitivity to sulfites (if formulation contains sulfites),Ventricular fibrillation
History of complex sleep behaviors after taking zolpidem,Hypersensitivity to zolpidem or any component of the formulation,Use in combination with alcohol or other CNS depressants is not recommended (relative)
No significant food interactions. However, patients on INTROPIN may have underlying conditions requiring dietary modifications (e.g., low sodium for hypertension). Avoid tyramine-rich foods if also taking MAOIs, though not a direct interaction with dopamine itself.
Avoid high-fat meals or heavy food immediately before or after administration, as food delays absorption and reduces peak concentration. Grapefruit juice may increase zolpidem levels; avoid concomitant use. No specific dietary restrictions beyond timing of dose.
Pregnancy Category C. In first trimester, animal studies show fetal abnormalities (e.g., skeletal and visceral malformations) at high doses. Second and third trimesters: risk of reduced uteroplacental blood flow and fetal hypoxia due to vasoconstriction; may induce preterm labor.
Zolpidem (ZOLPIMIST) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects at high doses, but adequate human studies are lacking. First trimester: Possible increased risk of congenital malformations, though data are limited. Second and third trimesters: Risk of fetal exposure to CNS depressant effects, including hypotonia, respiratory depression, and withdrawal symptoms in neonates after chronic use. Late third trimester use may lead to neonatal sedation and floppy infant syndrome.
Excreted in breast milk in low concentrations; M/P ratio unknown. Potential for cardiovascular effects in infant; weigh benefits against risks.
Zolpidem is excreted into human breast milk. The milk-to-plasma ratio (M/P) is approximately 0.03-0.1, indicating low transfer. However, peak milk concentrations occur within 2-3 hours after maternal dose. Breastfeeding is generally not recommended during zolpidem therapy due to potential infant sedation and impaired feeding. If used, advise to avoid breastfeeding for at least 6 hours after dose to minimize exposure.
No specific dose adjustment required; start at low doses and titrate to effect due to altered hemodynamics and increased plasma volume in pregnancy.
Pregnancy increases the volume of distribution and hepatic metabolism of zolpidem, potentially reducing drug concentrations. However, safety data are insufficient to recommend routine dose escalation. Use the lowest effective dose for the shortest duration. Avoid chronic use. If needed, initiate at 5 mg for non-elderly patients. Monitor for response and adjust cautiously, but no standard dose adjustment is mandated.
INTROPIN (dopamine) is a catecholamine with dose-dependent effects: low dose (1-5 mcg/kg/min) stimulates D1 receptors causing renal vasodilation; intermediate dose (5-10 mcg/kg/min) activates β1 receptors increasing cardiac contractility and heart rate; high dose (>10 mcg/kg/min) stimulates α1 receptors leading to vasoconstriction. Monitor for extravasation as it can cause tissue necrosis; treat with phentolamine infiltration. Taper infusion gradually to avoid hypotension. Contraindicated in pheochromocytoma and uncorrected tachyarrhythmias.
Zolpimist (zolpidem tartrate oral spray) is a non-benzodiazepine hypnotic for short-term insomnia treatment. Administer immediately before bedtime on an empty stomach. Effects may be delayed if taken with food. Avoid concurrent alcohol or CNS depressants. Use lowest effective dose, especially in elderly or debilitated patients (5 mg vs 10 mg). Monitor for complex sleep behaviors (sleep-driving, preparing/eating food, making phone calls while asleep). Discontinue if these occur. Tolerance may develop after 2 weeks; limit use to 7-10 days. Withdrawal symptoms possible after prolonged use. Contraindicated in patients with prior complex sleep behavior on zolpidem.
This medication is given intravenously and requires continuous monitoring in a hospital setting.,Report any pain, burning, or swelling at the IV site immediately.,You may experience increased heart rate, chest pain, or shortness of breath; notify staff promptly.,Inform your healthcare provider if you have a history of irregular heartbeat, high blood pressure, or thyroid disease.,Do not stop or change the infusion rate; it is controlled by medical staff.
Take this medication right before you get into bed and only if you have a full 7-8 hours to sleep.,Do not take with or immediately after a meal, as food can make it work more slowly.,Avoid drinking alcohol while using this medication, as it can increase side effects.,You may still feel sleepy the next day; avoid driving or hazardous activities until you know how the drug affects you.,Report any unusual behaviors during sleep such as driving, eating, or making phone calls to your healthcare provider immediately.,Do not take more than one dose per night or exceed the prescribed dose.,This medication is for short-term use only (usually 7-10 days); do not stop abruptly without consulting your doctor.,Store at room temperature away from heat and open flame. This product contains alcohol and is flammable.
No interactions on record
No interactions on record
Common clinical questions about INTROPIN vs ZOLPIMIST, answered by our medical review team.
INTROPIN is a Catecholamine Vasopressor that works by Dopamine is a direct agonist at dopamine (D1 and D2) and beta-1 adrenergic receptors, and at higher doses, alpha-1 adrenergic receptors. It also causes release of norepinephrine from sympathetic nerve terminals.. ZOLPIMIST is a Sedative-Hypnotic (Non-benzodiazepine) that works by Zolpidem is a nonbenzodiazepine hypnotic that binds selectively to the benzodiazepine type 1 (BZ1) receptor on the alpha1 subunit of the GABA-A chloride ion channel complex, potentiating the inhibitory effects of GABA.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INTROPIN and ZOLPIMIST depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INTROPIN is: 2-20 mcg/kg/min continuous IV infusion, titrated to achieve desired hemodynamic response. Typical initial dose: 5 mcg/kg/min.. The standard adult dose of ZOLPIMIST is: 5 mg orally once daily at bedtime, maximum 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INTROPIN and ZOLPIMIST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INTROPIN is classified as Category C. Pregnancy Category C. In first trimester, animal studies show fetal abnormalities (e.g., skeletal and visceral malformations) at high doses. Second and third trimesters: risk of re. ZOLPIMIST is classified as Category C. Zolpidem (ZOLPIMIST) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects at high doses, but adequate human studies are lacking. First trimester. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.